Ginkgo Bioworks Holdings (DNA) Work In Process (2021)

Ginkgo Bioworks Holdings' (DNA) quarterly Work In Process came in at $50000.0 in Q4 2021, down 69.33% on a QoQ basis from $163000.0 in Q3 2021.

Ginkgo Bioworks Holdings (DNA) Work In Process (2021) Analysis & Trends

Ginkgo Bioworks Holdings (DNA) has 1 years of Work In Process data on file, last reported at $50000.0 in Q4 2021.

  • Quarterly Work In Process changed N/A year-over-year to $50000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $50000.0 (changed N/A YoY) and the FY2021 annual result came in at $50000.0, changed N/A from the prior year.
  • Work In Process fell to $50000.0 in Q4 2021, from $163000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $163000.0 in Q3 2021 to a low of $50000.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Ginkgo Bioworks Holdings 432.60 Mn 348.06 Mn 18.44 Mn

Historic Data

Download Data
DateValue
Dec 31, 2021 50,000.00
Sep 30, 2021 163,000.00